The EPS beat is entirely non-operational (warrant revaluation) and irrelevant for a $3M market cap pre-revenue biotech. Focus on cash runway: $6.4M at $3.1M/quarter burn implies funding into late 2026, not 2027 as stated — dilution risk remains high. IM1240 preclinical data is early-stage; no catalyst until IND filing or partnership. Monitor for capital raise or partnering news on CM24/NT219.
Price Chart
Executive Summary
Purple Biotech reported Q1 2026 EPS of -$0.17, beating consensus of -$0.38 by 55.3%, but this is a clinical-stage biotech with no revenue and a $3M market cap. The company highlighted progress on its CAPTN-3 platform (IM1240 tri-specific antibody) with new preclinical data, but operating cash burn increased to $3.1M and cash runway extends only into 2027. The EPS beat is a mechanical artifact of warrant-related finance income ($2.2M), not operational improvement.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.17 vs consensus -$0.38 (55.3% beat), but driven by $2.2M non-cash warrant finance income
- No revenue; pre-revenue clinical-stage biotech with $6.4M cash as of March 31, 2026
- Operating cash burn $3.1M in Q1 2026 vs $2.0M in Q1 2025, cash runway into 2027
- R&D expenses $1.2M (up from $0.8M YoY) driven by CAPTN-3 CMC activities
- Adjusted operating loss $2.1M vs $1.3M YoY, reflecting higher operating expenses
- IM1240 preclinical data showed activity across treatment-resistant tumor samples; advancing toward first-in-human studies in 2027
- CM24 and NT219 development paused pending partnering or additional investment
Financial Impact
EPS beat of $0.21 vs consensus is non-operational; cash burn rate of ~$3.1M/quarter suggests ~6 months of runway at current spend
Risk Factors
- Cash runway may be shorter than stated if burn rate increases; likely need for dilutive financing within 12 months
- CM24 and NT219 development paused — pipeline concentration risk on early-stage CAPTN-3 platform
- No revenue and no near-term clinical data catalysts; stock is highly speculative with $3M market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295734 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 6-K | $1.74 $1.55 | ▼ −11.21% | ▼ −10.71% | $1.51 (−13.22%) |
Sep 2, 2026 4w ago | 6-K | $1.98 $1.74 | ▼ −12.12% | ▼ −11.16% | $1.51 (−23.74%) |
Aug 10, 2026 7w ago | 6-K | $1.55 $1.56 | ▲ +0.65% | ▲ +1.05% | $1.51 (−2.58%) |
Aug 7, 2026 8w ago | 6-K | $1.43 $1.50 | ▲ +4.90% | ▲ +4.50% | $1.51 (+5.59%) |
May 15, 2026 20w ago | Press Release | $3.94 $2.88 | ▼ −26.90% | ▼ −27.87% | $1.51 (−61.68%) |
Apr 27, 2026 22w ago | 6-K | $4.59 $4.22 | ▼ −8.06% | ▼ −8.46% | $1.51 (−67.10%) |
Apr 23, 2026 23w ago | 6-K | $4.55 $4.23 | ▼ −7.03% | ▼ −8.51% | $1.51 (−66.81%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.51 (−63.17%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.51 (−63.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access